Clinical trials: Urinary Complications
Urinary Retention, Catheter-Associated Urinary Tract Infection
Effectiveness and Cost-effectiveness of the T-Control® Catheter in Patients With Acute Urine Retention
The general purpose of this study is to assess the preliminary effectiveness and cost-effectiveness of the T-Control® catheter versus the Foley type catheter in patients with Acute Urine Retention.
- Conditions
- Urinary Retention, Catheter-Associated Urinary Tract Infection, Catheter Complications
- Trial name
- NCT05643950
- Testing
- Foley catheter, T-Control catheter
- Where
- 2 sites in Spain
- Sponsor
- Rethink Medical SL
Cystoscope, Lower Urinary Tract Symptoms
Evaluation of Performance and Safety of Ambu® aScope™ 4 Cysto and aView™ Urologia for Flexible Cystoscopy
In this study, the new aScope 4 Cysto is used to see if this new single use, flexible cystoscope performs as well as other routinely used flexible cystoscopes.
- Conditions
- Cystoscope, Lower Urinary Tract Symptoms, Bladder Disease
- Trial name
- NCT04192474
- Testing
- Flexible cystoscopy
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 83 people
- Sponsor
- Ambu A/S
Urinary Tract Infections
Morbidity Rate for UTI Through Use of PCR-Based Diagnosis and Management
This retrospective study is to determine if the use of PCR for detection and identification of pathogens in UTI along with antimicrobial susceptibility information, affords more efficacious treatment of UTI, as compared to…
- Trial name
- NCT04108910
- Testing
- Guidance UTI
- Volunteers
- 66,381 people
- Sponsor
- Pathnostics
Renal Calculi, Kidney Stones
Clinical Evaluation of BackStop in Patients Undergoing Intraureteric Stone Lithotripsy
The purpose of this clinical study is to evaluate BackStop, a polymer-based device that is intended to be used during ureteroscopic lithotripsy to prevent retrograde stone migration.
- Trial name
- NCT00893282
- Testing
- BackStop, Intracorporeal lithotripsy without the use of an anti-retropulsion device
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- Pluromed, Inc.
Bladder Neoplasms
A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)
The purpose of this first-in-human study is to determine the safety and tolerability of SCH 721015 in subjects with transitional cell carcinoma of the bladder.
- Trial name
- NCT00536588
- Testing
- SCH 721015 with SCH 209702
- Volunteers
- 17 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Urinary Incontinence, Erectile Dysfunction
Intraoperative Nerve Monitoring During Robot-assisted Laparoscopic Prostatectomy
The purpose of this study is to determine whether the use of intraoperative nerve monitoring during robotic-assisted laparoscopic prostatectomy surgery improves post-surgery urinary continence and erectile function.
- Trial name
- NCT02446808
- Testing
- Intraoperative nerve monitoring
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- ProPep Surgical, LLC
Urinary Incontinence
A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
Overactive bladder is very prevalent in postmenopausal women. The current study is designed to investigate whether a new drug may offer safe and effective treatment.
- Trial name
- NCT00231790
- Testing
- MK-0634 50 mg, MK-0634 125 mg
- Volunteers
- 848 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignant Solid Tumor, Solid Tumor Cancer
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer.
- Trial name
- NCT07337525
- Testing
- PLT012
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pilatus Biosciences Inc
Urinary Incontinence
Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence
The purpose of this study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 160 implanted female patients in which two adjustable balloons (one on each side of the urethra) are…
- Trial name
- ACT (NCT00113555)
- Testing
- ACT (Adjustable Continence Therapy)
- Where
- 7 sites in United States, Canada
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Uromedica
High-Risk Non-Muscle-Invasive Bladder Cancer
Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®
The RUTIVAC-1 study is a Phase I Clinical Trial designed to evaluate the systemic and mucosal immunological response and provide safety information after the use of RUTI® administration to individuals with NMIBC.
- Trial name
- RUTIVAC-1 (NCT03191578)
- Testing
- RUTI®
- Where
- Spain
- Volunteers
- 44 people
- Sponsor
- Archivel Farma S.L.
Urinary Incontinence
Clinical Trial of New Single-use Compact Intermittent Catheter
The study is a randomised, single-blinded, controlled crossover study. The total study duration for the individual subject will be between two days - two weeks, consisting of three site visits.
- Trial name
- NCT05841004
- Testing
- Investigational device, Comparator device
- Where
- Denmark
- Volunteers
- 73 people
- Sponsor
- Coloplast A/S
Cancer, Solid Tumor
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay.
- Conditions
- Cancer, Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- MARIA (NCT05219734)
- Testing
- Personalized Cancer Monitoring (PCM)
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- Invitae Corporation
Overactive Bladder
Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design
- Trial name
- REMOTE (NCT01302938)
- Testing
- Tolterodine ER
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Urinary Bladder, Overactive
A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics
This is a 12 month non-interventional study with solifenacin succinate, evaluating the effect of solifenacin on quality of life (QoL) of patients previously treated with antimuscarinics (Males and Females with Overactive Bladder…
- Trial name
- VEST (NCT02087098)
- Testing
- Solifenacin
- Where
- 60 sites in Czechia
- Volunteers
- 2,000 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Tract Infections
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation…
- Trial name
- NCT06702449
- Testing
- Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1
- Where
- 8 sites in United States, South Africa
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunotherapy, Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- ELEPHAS-02 (NCT05520099)
- Testing
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Where
- 12 sites in United States
- Volunteers
- 416 people
- Sponsor
- Elephas
Urinary Incontinence, Stress
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
A study designed to assess the efficacy, toleration and safety of SS-RBX for the treatment of stress urinary incontinence.
- Trial name
- NCT00138749
- Testing
- SS-RBX
- Where
- 95 sites in United States, Canada
- Volunteers
- 402 people
- Sponsor
- Pfizer
Overactive Bladder
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
This study will design an alternative urodynamic platform to better evaluate treatment effects of medications for overactive bladder. Part II is dependent on results of Part I and may not be conducted.
- Trial name
- NCT00768521
- Testing
- tolterodine tartrate
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Neurogenic Bladder
Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury
Subjects with neurogenic bladder secondary to spinal cord injury that is refractory to medical treatment and requires augmentation cystoplasty will be enrolled.
- Trial name
- NCT00512148
- Testing
- Autologous neobladder construct
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Tengion
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.